Kolonbo Biotech-B is now up nearly 12%. Clinical trial applications for new drugs SKB571 and SKB535 have both been approved.

KOLUNBOTAI BIO-B (06990) surged 11.68% in early trading, now reported at HKD 176.90, with a transaction amount of 60.9721 million HKD. Recently, KOLUNBOTAI BIO announced that on November 15, 2024, it received the clinical trial notice for the clinical trial application of the innovative drug SKB535 developed by the company from the National Medical Products Administration (NMPA) Drug Evaluation Center.

Sina Hong Kong stocksNov 19 22:56 ET

Guosheng Securities: The trend of the domestic innovative drug industry is gradually shifting from license-in to license-out.

Against the backdrop of fierce competition and internal circulation of innovative drug targets in the domestic market, going global is expected to break through the profit ceiling of the domestic market and follow the trend of global innovation.

Zhitong FinanceNov 18 02:00 ET

China Approves Clinical Trial for SKB's Anti-Tumor Drug; Shares Fall 4%

MT NewswiresNov 18 01:13 ET

Celon PharmaHygiene-B (06990.HK): SKB571 new drug clinical trial application approved by the National Medical Products Administration.

On November 18, GELON Group announced that Kelun-Botai Biotechnology-B (06990.HK) has received approval from the National Medical Products Administration's drug review center for the clinical trial application of its new drug SKB571 on November 15, 2024. According to the disclosure, SKB571 is a new type of dual-antibody ADC, primarily targeting multiple solid tumors such as lung cancer and gastrointestinal tumors. By employing a scientific approach to target combination selection and differentiated dual-antibody molecular design, it enhances the targeting of tumors and aids in overcoming tumor heterogeneity to improve efficacy.

Gelonghui FinanceNov 17 18:54 ET

Express News | Sichuan Kelun-Biotech Biopharmaceutical - Investigational New Drug Approval for Skb571 by Nmpa

ReutersNov 17 18:49 ET

Bo Pharm (02142) has submitted a new drug clinical trial application for the treatment of chronic obstructive pulmonary disease to the National Medical Products Administration.

Jingu News | Hubei Pharmaceuticals (02142) announced that the Group has submitted an application for a new drug clinical trial (IND) of HBM9378 (or SKB378, as described by Sichuan Kellon Biomedical Pharmaceutical Co., Ltd. (06990) and the Group's development partner of HBM9378) to the National Medical Products Administration. The drug is a fully human antibody targeting thymic stromal lymphopoietin ("TSLP"), used to treat chronic obstructive pulmonary disease ("COPD").

Jingu financial newsNov 8 04:09 ET